GPCR (structuretx.com) Market Value to Book Value Ratio

Official company branding of Structure Therapeutics Inc (GPCR)

Structure Therapeutics (GPCR) minimizes capital expenditures by outsourcing formula development and testing to external contractors. Thanks to its unique oral solutions, the startup is positioning itself for a significant niche in the weight loss segment, avoiding price wars. Revenue is based on the market launch of innovative diabetes pills, where the metric stands at 1.10. Serving as a valuation tool, this price chart clearly visualizes the dynamics of this asset.

GPCR Structure Corp: Market Value to Book Value in the range 04/28/2023 - 10/27/2026

Financial and market metric breakdowns for Structure Therapeutics Inc (GPCR)

- price and consensus price forecast:
Price Chart Structure Therapeutics|GPCR - Fair Value Consensus
- market capitalization data:
Market Value Structure Pharma|GPCR - Full Business Value
- book capitalization data:
Book Value per Share Structure Therapeutics|GPCR - Accounting Value of Company|Market Capitalization to Book Value Ratio structuretx.com|GPCR - Company Total Assets
- debt and liquidity data:
Debt to Equity Structure Therapeutics|GPCR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Structure Pharma|GPCR - Company Total Debt|Debts to Book Capitalization Structure Pharma
Initial company analysis:Structure Therapeutics - GPCR
Original product of Structure Pharma

This ratio determines the market value premium over net assets, separating the objective value of the balance sheet from the subjective expectations of investors. By analyzing the relationship between the market valuation of Structure Therapeutics (GPCR) and its book value, it becomes evident that the high valuation of Structure Therapeutics (GPCR) is driven not by current resources, but by the potential for future clinical success in the development of metabolic drugs amid low cash flow predictability.

Main competitors

Market Value to Book Value Ratio Ascendis Pharma A/S ASND|MDGL (madrigalpharma.com) - Market Value to Book Value|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio mimedx.com (MDXG)|Rezolute (RZLT) - Market Cap to Net Assets Ratio|Market Value to Book Value LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Market Capitalization to Book Value Ratio|sagimet.com (SGMT) - Market-to-Book Ratio|BIOA - Market Cap to Net Assets Ratio|Biomea Fusion Inc (BMEA) - Market Cap to Book Value Multiple|QNCX (Quince Therapeutics Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Fractyl Health, Inc|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio RDUS (Radius Pharmaceuticals)